Suppr超能文献

法尼基蛋白转移酶抑制剂ZARNESTRA R115777——一项发现的历程。

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.

作者信息

Venet Marc, End David, Angibaud Patrick

机构信息

Johnson & Johnson Pharmaceutical Research, Campus de Maigremont, BP 615, 27106 Val de Reuil Cedex, France.

出版信息

Curr Top Med Chem. 2003;3(10):1095-102. doi: 10.2174/1568026033452050.

Abstract

R115777 (R)-6-amino[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice. Taking its roots into Janssen's ketoconazole and retinoic acid catabolism programs, our interest into Ras prenylation process led us stepwise to identify the key structural features of R115777. Methodology, structure activity relationships, and pharmacology will be presented. R115777 is currently in phase III clinical evaluation.

摘要

R115777(R)-6-氨基[(4-氯苯基)(1-甲基-1H-咪唑-5-基)甲基]-4-(3-氯苯基)-1-甲基-2(1H)-喹啉酮是一种强效且具有选择性的法尼基蛋白转移酶抑制剂,在小鼠口服给药后,在体内具有显著的抗肿瘤作用。基于杨森公司的酮康唑和视黄酸分解代谢项目,我们对Ras异戊二烯化过程的兴趣促使我们逐步确定了R115777的关键结构特征。本文将介绍其方法、构效关系和药理学。R115777目前正处于III期临床评估阶段。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验